RWE 201 – EU – EMA Big Data Steering Group Updates Its Workplan to Accelerate Transformation to Data-Driven Medicines Regulation

Updated EMA Big Data Steering Group Workplan: https://www.ema.europa.eu/en/documents/work-programme/workplan-2023-2025-hma/ema-joint-big-data-steering-group_en.pdf

The Heads of Medicines Agencies (HMA) and European Medicines Agency (EMA) Big Data Steering Group workplan has been enhanced including work on national regulatory use cases for real-world evidence (RWE), intensified work on artificial intelligence (AI) and public consultation on patient experience data (PED).

The updated Big Data Steering Group (BDSG) workplan continues to evolve to integrate use of big data and data analytics in medicines regulation. he updated workplan contains the following key additions:

[1] Real-world evidence (RWE): DARWIN EU® will address use cases from national regulators and learnings from RWE pilots will be gathered and published.  Work on RWE guidance, at EU and international level, will be informed by public consultations and collaboration with international regulators under the umbrella of ICH will continue.

[2] Real World Data (RWD) quality considerations will be published following a public consultation.

[3] Engagement with patients’ organisations will intensify through a public consultation on Patient Experience Data (PED), dialogue on training needs, workshop on patient registries, a call to populate the metadata and RWD source catalogues with PED, and exploration of use cases to analyse PED to establish their role in regulatory decision-making process.

[4] Analysis of additional data types will be explored with the development of use cases for genomics data, the launch of a ‘proof of concept’ on non-clinical raw data analysis and discussion on Chemistry, Manufacturing and Controls (CMC) data analysis.

[5] Experimentation of advanced analytics, including AI, will continue and the first AI knowledge mining tool for core regulatory processes will be released to the EU regulatory network.

[6] The future European Medicines Regulatory Network data strategy will be developed to prepare for publication in 2025.

A full overview of the timeline can be found here: https://www.ema.europa.eu/en/documents/work-programme/workplan-2023-2025-hma/ema-joint-big-data-steering-group_en.pdf

Share this story...
EU – EMA’s 2025 Vision for RWE

November 5, 2023|2023, RWE 201|

RWE 201 - EU – EMA’s 2025 Vision for RWE   EMA 2025 Vision: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299492/ EMA RWE Framework Report: https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained_en.pdf The European Medicines Agency (EMA) isn't simply relying [...]

EU – The Data Governance Act

October 14, 2023|2023, RWE 201|

RWE 201 - EU – The Data Governance Act  Data Governance Act: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022R0868The EU Data Governance Act (DGA) aims to establish a legal framework for data sharing across sectors. [...]

EU – The European Health Data Space

October 14, 2023|2023, RWE 201|

RWE 201 - EU - The European Health Data Space [Image Source: https://tehdas.eu/results/tehdas-identifies-user-journey-for-cross-border-health-data-sharing/]EHDS: https://health.ec.europa.eu/ehealth-digital-health-and-care/european-health-data-space_enThe European Health Data Space (EHDS) is an initiative by the European Commission to foster the [...]

EU – EU4Health Program

October 14, 2023|2023, RWE 201|

RWE 201 - EU - EU4Health Program EU4Health: https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthier-european-union_enEU4Health is an ambitious EU health program for the years 2021-2027. Its primary goal is to bolster the resilience of Europe's [...]